Turning ideas into digital impact.
At BI X, we explore digital opportunities across the entire Pharma value chain. Each initiative begins with an open question, becomes tangible through experimentation, and gains direction through evidence-based validation. We co-create with colleagues across Boehringer Ingelheim and with external innovators. Insights guide our decisions. Testing shapes our approach. Iteration keeps us moving forward. In our portfolio you’ll find initiatives ranging from digital biomarkers and AI-driven platforms to tools that support scientists, clinicians, and field teams.
Each one reflects how we work: curious, fast, hands-on, and focused on what makes a real difference.
How We Work.
At BI X, we explore early, test boldly, and validate what creates real value. Our way of working combines scientific rigor with entrepreneurial speed — structured, transparent, and purpose-driven.
We work in small, cross-functional teams with the freedom to explore digital opportunities independently while staying closely aligned with Boehringer Ingelheim’s strategic needs.
These cells bring together exactly the expertise needed for the challenge at hand: from data science and engineering to UX, strategy, and domain knowledge. They move fast, make progress visible early, and adjust as they learn.
We work hands-on with internal teams and expert partners to:
With deep business insight, digital dedication, and methodology designed for exploration and innovation, we help build the capabilities to stay ahead.
Unmet needs
Understand unmet needs across the pharma value chain: from research and development to operations and beyond.
Tech Scouting
Explore technological possibilities to address these needs.
User
Design and run structured experiments to test assumptions and develop initial prototypes.
Evidence
Generate evidence that enables clear and confident decisions.
Our Focus Areas.
We explore, test, and validate digital technologies with the potential to meaningfully shape the future of human and animal health.
Exploring AI-driven insights, decision support, automation, and predictive capabilities that can strengthen research, development, and operations, and other areas across the pharma value chain.
Testing emerging ways to measure health: from continuous monitoring to new digital endpoints and remote assessment methods.
Understanding how people interact with digital tools. Experimenting with emerging technologies — from edge computing to new interaction paradigms — and assessing their relevance for Boehringer Ingelheim.
Wherever digital innovation can create value, we explore its potential.